Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC2A1 | P11166 | 4/20 | 0.34 |
| ▸ | NCEH1 | Q6PIU2 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | RECQL | P46063 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29880175 | 1.00 | SLC2A1 (0.34) | SLC2A1NCEH1KDM4EMAPTRECQL | |
| SCHEMBL22536765 | 0.94 | NCEH1 (0.36) | SLC2A1NCEH1KDM4EMAPTRECQL | |
| SCHEMBL29879820 | 0.90 | ACHE (0.32) | SLC2A1NCEH1 | |
| SCHEMBL22536817 | 0.88 | NCEH1 (0.34) | SLC2A1NCEH1KDM4EMAPTRECQL | |
| SCHEMBL29880050 | 0.88 | NCEH1 (0.34) | SLC2A1NCEH1KDM4EMAPTRECQL | |
| SCHEMBL22536766 | 0.88 | NCEH1 (0.33) | SLC2A1NCEH1KDM4EMAPTRECQL | |
| SCHEMBL29880244 | 0.85 | NCEH1 (0.32) | NCEH1KDM4EMAPTRECQLKMT2A | |
| SCHEMBL22536819 | 0.85 | NCEH1 (0.32) | NCEH1KDM4EMAPTRECQLKMT2A | |
| SCHEMBL22536818 | 0.85 | NCEH1 (0.32) | NCEH1KDM4EMAPTRECQLKMT2A | |
| SCHEMBL29880441 | 0.85 | NCEH1 (0.32) | NCEH1KDM4EMAPTRECQLKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10800752-B2 | Substituted naphtho[2,3-b]furans as water-soluble prodrugs for preventing and/or treating cancer | BOSTON BIOMEDICAL, INC. (US) | 2020-10-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10800752-B2 | Substituted naphtho[2,3-b]furans as water-soluble prodrugs for preventing and/or treating cancer | NR0B1, NR0B2, NR2C2 | SLC2A1 461/4885NCEH1 966/4885KDM4E 3479/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.